Drug Profile
Plamotamab - Xencor
Alternative Names: CD20 x CD3; XmAb 13676Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diffuse large B cell lymphoma
- Phase I Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 04 Mar 2024 Phase-I development is ongoing in Non-Hodgkin's lymphoma (Second-line therapy or greater) in France and USA (Parenteral) (NCT02924402)
- 27 Feb 2024 Phase-I development is ongoing in Chronic lymphocytic leukaemia (Second-line therapy or greater) in France and USA (IV, Infusion) (NCT02924402)
- 27 Feb 2024 Phase-I development is ongoing in Diffuse large B cell lymphoma (Second-line therapy or greater) in France (IV, Infusion) (NCT02924402)